CA2530140A1 - Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof - Google Patents

Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof Download PDF

Info

Publication number
CA2530140A1
CA2530140A1 CA002530140A CA2530140A CA2530140A1 CA 2530140 A1 CA2530140 A1 CA 2530140A1 CA 002530140 A CA002530140 A CA 002530140A CA 2530140 A CA2530140 A CA 2530140A CA 2530140 A1 CA2530140 A1 CA 2530140A1
Authority
CA
Canada
Prior art keywords
alpha
hexan
beta
oxooxazolidin
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002530140A
Other languages
French (fr)
Other versions
CA2530140C (en
Inventor
Yasumichi Fukuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2530140A1 publication Critical patent/CA2530140A1/en
Application granted granted Critical
Publication of CA2530140C publication Critical patent/CA2530140C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

This invention relates to new oxazolidinones having a cyclopropyl moiety, which are effective against aerobic and anerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, Bacteroides spp., Clostridia spp. species, as well as acid-fast organisms such as Mycobacterium tuberculosis and other mycobactenial species. The compounds are represented by structural formula: (I): its enantiomer, diastereomer, or pharmaceutically acceptable salt or ester thereof.

Claims (15)

1. The present invention relates to compounds of formula I:

its enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof wherein:
R1 represents i) hydrogen, ii) (CH2)n NR5R6, iii) CR7R8R9, C(R)2OR14, CH2NHR14, iv) C(=O)R13, C(=NOH)H, C(=NOR13)H, C(=NOR13)R,3, C(=NOH)R13, C(=O)N(R13)2, C(=NOH)N(R13)2, NHC(=X1)N(R13)2, NRCO2R, (C=NH)R7, N(R13)C(=X1)N(R13)2, COOR13, SO2R14, N(R13)SO2R14, N(R13)COR14, v) (C1-6alkyl)CN, CN, CH=C(R)2, (CH2)POH, C(=O)CHR13, C(=NR13)R13, NR,oC(=X1)R13;
or vi) C5-10 heterocycle optionally substituted with 1-3 groups of R7, which may be attached through either a carbon or a heteroatom;

X represents ; ~or a C5-10 heteroaryl represented by which represents an optionally substituted aromatic heterocyclic group containing 1 to 4 nitrogen atoms and at least one double bond, and which is connected through a bond on any nitrogen said heteroaryl optionally substituted with 1 to 3 substitutents selected from R7 Y represents NR*, O, CN, or S(O)p;

represents aryl or heteroaryl, heterocycle, heterocyclyl or heterocyclic;
R3 represent NR(C=X2)R12, NR*R12, C6-10 aryl, or-(O)n C5-10 heterocyclyl which may be attached through either a carbon or a heteroatom; said aryl and heterocyclyl optionally substituted with 1-3 groups of R7, R4, R4a, R4b, and R4c independently represent i) hydrogen, ii) halogen, iii) C1-6 alkoxy, or iv) C1-6 alkyl;
r and s independently are 1-3, with the provision that when (R4a)s and (R4)r or(R4b) and (R4c)s are attached to an Ar or HAr ring the sum of r and s is less than or equal to 4;
R5 and R6 independently represent i) hydrogen, ii) C1-6 alkyl optionally substituted with 1-3 groups of halogen, CN, OH, C1-6 alkoxy, amino, imino, hydroxyamino, alkoxyamino, C1-6 acyloxy, C1-6 alkylsulfenyl, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, aminosulfonyl, C1-6 alkylaminosulfonyl, C1-6 dialkylaminosulfonyl, 4-morpholinylsulfonyl, phenyl, pyridine, 5-isoxazolyl, ethylenyloxy, or ethynyl, said phenyl and pyridine optionally substituted with 1-3 halogen, CN, OH, CF3, C1-6 alkyl or C1-6 alkoxy;
iii) C1-6 acyl optionally substituted with 1-3 groups of halogen, OH, SH, C1-6 alkoxy, naphthalenoxy, phenoxy, amino, C1-6 acylamino, hydroxylamino, alkoxylamino, C1-6 acyloxy, aralkyloxy, phenyl, pyridine, C1-6 alkylcarbonyl, C1-6 alkylamino, C1-6 dialkylamino, C1-6 hydroxyacyloxy, C1-6 alkylsulfenyl, phthalimido, maleimido, succinimido, said phenoxy, phenyl and pyridine optionally substituted with 1-3 groups of halo, OH, CN, C1-6 alkoxy, amino, C1-6 acylamino, CF3 or C1-6 alkyl;

iv) C1-6 alkylsulfonyl optionally substituted with 1-3 groups of halogen, OH, C1-6 alkoxy, amino, hydroxylamino, alkoxylamino, C1-6 acyloxy, or phenyl; said phenyl optionally substituted with 1-3 groups of halo, OH, C1-6 alkoxy, amino, C1-6 acylamino, CF3 or C1-6 alkyl;
v) arylsulfonyl optionally substituted with 1-3 of halogen, C1-6 alkoxy, OH or C1-6 alkyl;
vi) C1-6 alkoxycarbonyl optionally substituted with 1-3 of halogen, OH, C1-6 alkoxy, C1-6 acyloxy, or phenyl, said phenyl optionally substituted with 1-3 groups of halo, OH, C1-6 alkoxy, amino, C1-6 acylamino, CF3 or C1-6 alkyl;
vii) aminocarbonyl, C1-6 alkylaminocarbonyl or C1-6 dialkylaminocarbonyl, said alkyl groups optionally substituted with 1-3 groups of halogen, OH, C1-6 alkoxy or phenyl viii) five to six membered heterocycles optionally substituted with 1-3 groups of halogen, OH, CN, amino, C1-6 acylamino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonylamino, alkoxy, C1-6 acyloxy or C1-6 alkyl, said alkyl optionally substituted with 1-3 groups of halogen, or C1-6 alkoxy;
ix) C3-6 cycloalkylcarbonyl optionally substituted with 1-3 groups of halogen, OH, C1-6 alkoxy or CN;
x) benzoyl optionally substituted with 1-3 groups of halogen, OH, C1-6 alkoxy, C1-6 alkyl, CF3, C1-6 alkanoyl, amino or C1-6 acylamino;
xi) pyrrolylcarbonyl optionally substituted with 1-3 of C1-6 alkyl;
xii) C1-2 acyloxyacetyl where the acyl is optionally substituted with amino, C1-6 alkylamino, C1-6 dialkylamino, 4-morpholino, 4-aminophenyl, 4-(dialkylamino)phenyl, 4-(glycylamino)phenyl; or R5 and R6 taken together with any intervening atoms can form a 3 to 7 membered heterocyclic ring containing carbon atoms and 1-2 heteroatoms independently chosen from O, S, SO, SO2, N, or NR8;
R7 represent i) hydrogen, halogen, (CH2)p C5-10 heterocyclyl, CN, CO2R, CON(R)2, CHO, (CH2)0-3NHAc, C(=NOR), OH, C1-6 alkoxy, C1-6 alkyl, alkenyl, hydroxy C1-6 alkyl, (CH2)1-3NHC(O)C1-6 alkyl, (CH2)0-3N(C1-6 alkyl)2, NHCO2R, -OCOC1-6 alkyl;
ii) (CH2)n amino, (CH2)n C1-6 alkylamino, C1-6 acylamino, C1-6 dialkylamino, hydroxylamino or C1-2 alkoxyamino all of which can be optionally substituted on the nitrogen with C1-6 acyl, C1-6 alkylsulfonyl or C1-6 alkoxycarbonyl, said acyl and alkylsulfonyl optionally substituted with 1-2 of halogen or OH;

R8 and R9 independently represents i) H, CN, ii) C1-6 alkyl optionally substituted with 1-3 halogen, CN, OH, C1-6 alkoxy, C1-6 acyloxy, or amino, iii) phenyl optionally substituted with 1-3 groups of halogen, OH, C1-6 alkoxy; or R7 and R8 taken together can form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, SO2, NH, and NR8;
X1 represents O, S or NR13, NCN, NCO2R16, or NSO2R14 X2 represents O, S, NH or NSO2R14;
R10 represents hydrogen, C1-6 alkyl or CO2R15;
R12 represents hydrogen, C1-6 alkyl, NH2, OR, CHF2, CHCl2, C(R)2Cl, (CH2)n SR, (CH2)n CN, (CH2)n SO2R, (CH2)n S(O)R, C1-6 alkylamino, C3-6 cycloalkyl, C5-10 heterocyclyl or C1-6 dialkylamino, where said alkyl, and cycloalkyl may be substituted with 1-3 groups of halo, CN, OH
or C1-6 alkoxy, said heterocyclyl optionally substituted with 1-3 groups of R7;
Each R13 represents independently hydrogen, C1-6 alkyl, C6-10 aryl, NR5R6, SR8, S(O)R8, S(O)2 R8, CN, OH, C1-6 alkylS(O)R, C1-6 alkoxycarbonyl, hydroxycarbonyl, -OCOaryl, C1-6 acyl, C3-7 membered carbon ring optionally interrupted with 1-4 heteroatoms chosen from O, S, SO, SO2, NH
and NR8 where said C1-6 alkyl, aryl or C1-6 acyl groups may be independently substituted with 0-3 halogens, hydroxy, N(R)2, CO2R, C6-10 aryl, C5-10 heteroaryl, or C1-6 alkoxy groups;
When two R13 groups are attached to the same atom or two adjacent atoms they may be taken together to form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, SO2, NH, and NR8;
R represents hydrogen or C1-6 alkyl;
R* represents hydrogen, CN, C(=O)R14, (CH2)p CO2C1-6 alkyl, (CH2)p C5-10heterocyclyl, or C1-6 alkyl, said alkyl and heterocyclyl optionally substituted with 1 to 3 groups of R7;

R14 represents amino, C1-6 alkyl, C3-6 cycloalkyl, (CH2)p C5-10heterocyclyl, C1-6 haloalkyl, phenyl, said alkyl, cycloalkyl, phenyl, heterocyclyl optionally substituted with 1-3 group of R7, when R7 is an amino or hydroxyl group or a nitrogen that forms part of the heterocycle, said amino and hydroxy optionally protected with an amino or hydroxy protecting group;
R15 is C1-6 alkyl or benzyl said benzyl optionally substituted with 1-3 groups of halo, OH, C1-6 alkoxy, amino, C1-6 acylamino, or C1-6 alkyl;
R16 is hydrogen, C5-10heteroaryl, C6-10aryl, said heteroaryl and aryl optionally substituted with 1-3 groups of R7;
p represents 0-2 and n represents 0-1.
2. The compound according to claim 1 wherein Ar and HAr of independently are phenyl, pyridyl, pyrimidinyl, or piperidinyl, and r + s for a nd b combined <= 3.
3. The compound according to claim 2 wherein X is.
4. The compound according to claim 3 wherein Y is NR* and R1 is H, NR5R6, CN, OH, or CR7R8R9.
5. The compound according to claim 4 wherein R1 is NR5R6, or CN.
6. The compound according to claim 5 wherein R3 is C5-10 heteroaryl, said heteroaryl optionally substituted with 1-3 groups of R7.
7. The compound according to claim 1 wherein X is C5-10 heteroaryl represented by which represents an optionally substituted aromatic heterocyclic group containing 1 to 4 nitrogen atoms and at least one double bond, and which is connected through a bond on any nitrogen, said heterocyclic group optionally substituted with 1 to 3 substitutents selected from R7.
8. The compound according to claim 7 of the structural formula III:
wherein R4, R4a, are as previously described and R3 and independently are 1 ,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, tetrazole, pyrazole, or imidazole, any of which may contain 1 to 3 substitutents selected from R7,
9. The compound according to claim 1 of the structural formula IV:

wherein R4, Rya, are as described and R3 and independently are 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, tetrazole, pyrazole, or imidazole, any of which may contain 1 to 3 substitutents selected from R7,
10. A compound which is:
1-[5 (R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazo1e, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridiri-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, 1-[S(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-oxabicyclo[3.1.0)hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,.beta.)-6-t-butoxycarbonylamino-3-oxabicyclo[3.1.0)hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl)-1,2,3-triazole, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[3-Fluoro-4-[2-(1-methyltetrazol-5-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl)-1,2,3-triazole, 1-[5(R)-3-[3,5-Difluoro-4-[2-(1-methyltetrazol-5-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3,5-difluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3,5-difluorophenyl]-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl)-2-oxooxazolidin-5-ylmethyl)acetamide, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl)-3,5-difluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl)acetamide, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl)-3,5-difluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide S-oxide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide S,S-dioxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide, 4-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,4-triazole, 4-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,4-triazole, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-5-[N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one, 5(R)-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyl-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]oxazolidin-2-one, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-5-[N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]propionamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]difluoroacetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]cyclopropanecarboxamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]propionamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]propionamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]cyclopropanecarboxamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl]cyclopropanecarboxamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]difluoroacetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]difluoroacetamide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-methyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl)-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3,6-dicyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-[(1-t-butoxycarbonylaminocyclopropan-1-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-[(1-aminocyclopropan-1-yl)carbonyl]-6-cyano-3-azabicyclo [3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-[2-(phthalimid-2-yl)ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-(2-aminoethyl)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-[2-(1,2,4-triazol-4-yl)ethyl]-3-azabicyclo[3.1.0]

hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-bromoacetyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(morpholin-4-yl)acetyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(5-cyanopyridin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(1,3-dihydroxypropan-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-[((2S)-1-t-butoxycabonylpyrrolidin-2-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-[((2S)-pyrrolidin-2-yl)carbonyl]-3-azabicyclo[3.1.0]
hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-[((2S,4R)-1-t-butoxycabonyl-4-hydroxypyrrolidin-2-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-[((2S,4R)-4-hydroxypyrrolidin-2-yl)carbonyl]-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-[((2S,4S)-1-t-butoxycabonyl-4-fluoropyrrolidin-2-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-[((2S,4S)-4-fluoropyrrolidin-2-yl)carbonyl]-3-azabicyclo [3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-(t-butoxycarbonyl)amino-3-azabicyclo [3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole dihydrochloride, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-acetoxyacetyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-(2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-hydroxyacetyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, N-[5(S)-3-(4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-dichlorocyclopropane)-1-carboxamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-dichlorocyclopropane)-1-carboxamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-dichlorocyclopropane)-1-carboxamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-difluorocyclopropane)-1-carboxamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-difluorocyclopropane)-1-carboxamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-(2,2-difluorocyclopropane)-1-carboxamide, O-methyl-N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]
hexan-6-yl]- pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]carbamate, O-methyl-N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]carbamate, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3,6-dicyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-methyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[3-fluoro-4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-hydroxymethyl-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-fluoro-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-fluoro-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.3)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-fluoro-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-5-fluoro-1,2,3-triazole, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-5-fluoro-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-(4- t-butoxycarbonylpiperazin-1-yl)acetyl-6-cyano-3-azabicyclo [3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(piperazin-1-yl)acetyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole dihydrochloride, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-oxabicyclo[3.1.0]hexan-6-yl]thiophen-4-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(piperidin-1-yl)acetyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(pyrrolidin-1-yl)acetyl-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(4-dimethylaminopiperidin-1-yl)acetyl-3-azabicyclo [3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-[((2S)-1-t-butoxycabonylpyrrolidin-2-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-[((2S)-pyrrolidin-2-yl)carbonyl]-3-azabicyclo[3.1.0]
hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-[((2S,4R)-4-hydroxypyrrolidin-2-yl)carbonyl]-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-[((2S,4R)-1-t-butoxycabonyl-4-hydroxypyrrolidin-2-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-[((2S,4S)-1-t-butoxycabonyl-4-fluoropyrrolidin-2-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-[((2S,4S)-4-fluoropyrrolidin-2-yl)carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5 (R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5 (R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-t-butoxycarbonylamino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2.-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-amino-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(4-methylpiperazin-1-yl)acetyl-3-azabicyclo[3.1.0]
hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S-oxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-thiabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole S,S-dioxide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(1,3-diacetoxypropan-2-yl)-3-azabicyclo[3.1.0]
hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-[(3R,4S)-1-azabicyclo[2.2.1]hepan-3-yl]carbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one, (R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-5-[N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-(thiatriazol-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, N-[5 (S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]thioacetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]thioacetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]isothiocyanate, O-methyl-N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-t-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]
hexan-6-yl]-pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]
thiocarbamate, O-methyl-N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]thiocarbamate, or their enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof.
11 A compound according to claim 10, which is 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.3)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Amino-3-oxabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[3-Fluoro-4-[2-(1-methyltetrazol-5-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5 (R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3,5-difluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3,5-difluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, 1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 4-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,4-triazole, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one, 5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-5-[N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]cyclopropanecarboxamide, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]difluoroacetamide, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-3-[(1-Aminocyclopropan-1-yl)carbonyl]-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, or their enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof.
12. The compound according to claim 11, which is:
1-[5(R)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride, 1-[5(R)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole hydrochloride, N-[5(S)-3-[4-[4-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride, N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride, or N-[5(S)-3-[4-[2-[(1.alpha.,5.alpha.,6.beta.)-6-Cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride.
13. A pharmaceutical composition comprised of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier, said composition optionally in combination with a vitamin selected from the group consisting vitamin B2, vitamin B6, vitamin B12 and folic acid.
14. A method of treating or preventing a bacterial infection or an oxazolidinon-associated side effect in a mammalian patient in need thereof, comprising administering to 5.alpha.id patient an effective amount of a compound of claim 1 and optionally an effective amount of one or more of a vitamin selected from the group consisting of vitamin B2, vitamin B6, vitamin B12 and folic acid to a patient in need thereof.
15. A method according to claim 14 wherein the oxazolidinone associated side effect is normocyctic anemia, sideroblastic anemia, peripheral sensory neuropathy, optic neuropathy, seizures, thrombocytopenia, cheilosis, seborrheic dermatitis, hypo-regenerative anemia, or megaloblastic anemia.
CA2530140A 2003-07-02 2004-06-29 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof Expired - Fee Related CA2530140C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48390403P 2003-07-02 2003-07-02
US60/483,904 2003-07-02
US54698404P 2004-02-24 2004-02-24
US60/546,984 2004-02-24
PCT/US2004/020734 WO2005005398A2 (en) 2003-07-02 2004-06-29 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof

Publications (2)

Publication Number Publication Date
CA2530140A1 true CA2530140A1 (en) 2005-01-20
CA2530140C CA2530140C (en) 2010-11-09

Family

ID=34068173

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2530140A Expired - Fee Related CA2530140C (en) 2003-07-02 2004-06-29 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof

Country Status (23)

Country Link
US (2) US7462633B2 (en)
EP (1) EP1646629B1 (en)
JP (1) JP4607107B2 (en)
KR (1) KR20060113625A (en)
AR (1) AR044990A1 (en)
AT (1) ATE471937T1 (en)
AU (1) AU2004256083B2 (en)
BR (1) BRPI0411688A (en)
CA (1) CA2530140C (en)
CL (1) CL2004001678A1 (en)
DE (1) DE602004027811D1 (en)
EC (1) ECSP056257A (en)
IL (1) IL172785A0 (en)
IS (1) IS8178A (en)
MA (1) MA27938A1 (en)
MX (1) MXPA06000228A (en)
MY (1) MY140137A (en)
NO (1) NO20060558L (en)
NZ (1) NZ544237A (en)
PE (1) PE20050732A1 (en)
RU (1) RU2348628C2 (en)
TW (1) TW200510421A (en)
WO (1) WO2005005398A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897230B2 (en) * 2001-04-17 2005-05-24 Kyorin Pharmaceutical Co., Ltd. Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof
CA2528089C (en) 2003-06-03 2015-11-24 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
US8324398B2 (en) * 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
WO2005005422A1 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
JP4607107B2 (en) 2003-07-02 2011-01-05 メルク・シャープ・エンド・ドーム・コーポレイション Cyclopropyl-substituted oxazolidinone antibiotics and their derivatives
TW200526649A (en) * 2003-12-17 2005-08-16 Rib X Pharmaceuticals Inc Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (en) 2003-12-18 2008-08-26 동아제약주식회사 Novel oxazolidinone derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same for antibiotics
US20100286211A1 (en) * 2004-10-08 2010-11-11 Biswajit Das Oxazolidinone derivatives as antimicrobials
US8399660B2 (en) 2005-06-08 2013-03-19 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles
US20090018123A1 (en) * 2005-06-20 2009-01-15 Milind D Sindkhedkar Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation
US7838526B2 (en) * 2005-08-05 2010-11-23 Esther Baldinger Method of treating neurological disorders
AR054608A1 (en) * 2005-08-08 2007-06-27 Actelion Pharmaceuticals Ltd OXAZOLIDINONE DERIVATIVES LINKED TO QUINOLONES AS ANTIBACTERIALS
JP2010528007A (en) * 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション Cyclopropylpyrrolidine orexin receptor antagonist
EP2757104B1 (en) 2008-10-10 2019-08-14 Merck Sharp & Dohme Corp. Compounds used in the synthesis of oxazolidinones
CU24089B1 (en) 2009-02-03 2015-04-29 Trius Therapeutics CRYSTALLINE FORM OF DIHYDROGEN PHOSPHATE R) -3- (4- (2- (2-METHYLTRETAZOL-5-IL) -3-FLUOROPHENYL) -5-HYDROXIMETHYL OXAZOLIDIN-2-ONA
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
RU2012102094A (en) 2009-06-26 2013-08-10 Панацеа Биотек Лтд. New azabicyclohexanes
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053593A (en) * 1975-11-26 1977-10-11 Lew Frumoff Medical product combining antimicrobial, antiporasitic and vitamin complex
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
WO1993009103A1 (en) * 1991-11-01 1993-05-13 The Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
CA2147753C (en) 1992-12-08 2004-08-03 Michael Robert Barbachyn Tropone-substituted phenyloxazolidinone antibacterial agents
TW286317B (en) 1993-12-13 1996-09-21 Hoffmann La Roche
DE4425612A1 (en) * 1994-07-20 1996-04-04 Bayer Ag 6-membered nitrogen-containing heteroaryl oxazolidinones
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
MX9708627A (en) 1995-05-11 1998-02-28 Upjohn Co Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones.
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
DE60035330T2 (en) 1999-05-14 2008-03-06 Kabushiki Kaisha Toshiba, Kawasaki SURFACE WAVE FILTER
US6608081B2 (en) * 1999-08-12 2003-08-19 Ortho-Mcneil Pharmaceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
US20010047004A1 (en) 2000-02-10 2001-11-29 Hester Jackson B. Oxazolidinone thioamides with piperazine amide substituents
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
AU5889701A (en) * 2000-06-05 2001-12-17 Dong A Pharm Co Ltd Novel oxazolidinone derivatives and a process for the preparation thereof
JP2004504321A (en) 2000-07-17 2004-02-12 ランバクシー　ラボラトリーズ　リミテッド Oxazolidinone derivatives as antimicrobial agents
AU2001293163A1 (en) * 2000-09-27 2002-04-08 Lynx Therapeutics, Inc. Method for determining relative abundance of nucleic acid sequences
ES2256331T3 (en) 2000-12-21 2006-07-16 PHARMACIA &amp; UPJOHN COMPANY LLC ANTIMICROBIAL QUINOLINE DERIVATIVES AND USE OF THE SAME TO TREAT BACTERIAL INFECTIONS.
YU52403A (en) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
US6897230B2 (en) * 2001-04-17 2005-05-24 Kyorin Pharmaceutical Co., Ltd. Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof
CA2463794A1 (en) 2001-11-29 2003-06-12 Merck & Co., Inc. Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof
CN1155585C (en) 2001-12-19 2004-06-30 中国医学科学院医药生物技术研究所 3,5-substituted oxazolidinone derivative and its preparing process and application
TW200302095A (en) 2002-01-25 2003-08-01 Upjohn Co Oxazolidinone cotherapy
US7141588B2 (en) * 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
AR038536A1 (en) 2002-02-25 2005-01-19 Upjohn Co N-ARIL-2-OXAZOLIDINONA-5- CARBOXAMIDS AND ITS DERIVATIVES
PL372191A1 (en) 2002-02-28 2005-07-11 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
BR0310074A (en) 2002-05-15 2005-03-08 Ranbaxy Lab Ltd Polymorphic forms of phenyl oxazolidinone derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
US7498350B2 (en) * 2002-11-28 2009-03-03 Astrazeneca Ab Oxazolidinones as antibacterial agents
TW200500360A (en) * 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
WO2004089943A1 (en) 2003-04-09 2004-10-21 Pharmacia & Upjohn Company Llc Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues
EP1625124A1 (en) 2003-05-06 2006-02-15 Ranbaxy Laboratories, Ltd. Oxazolidinone derivatives as antimicrobials
JP4607107B2 (en) * 2003-07-02 2011-01-05 メルク・シャープ・エンド・ドーム・コーポレイション Cyclopropyl-substituted oxazolidinone antibiotics and their derivatives
JP2007521283A (en) 2003-07-02 2007-08-02 メルク アンド カンパニー インコーポレーテッド Oxazolidinone antibiotics and derivatives thereof substituted with cyclopropyl groups
WO2005005422A1 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
WO2005005399A1 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof

Also Published As

Publication number Publication date
PE20050732A1 (en) 2005-11-02
US7582659B2 (en) 2009-09-01
MXPA06000228A (en) 2006-06-27
US7462633B2 (en) 2008-12-09
ECSP056257A (en) 2006-04-19
DE602004027811D1 (en) 2010-08-05
BRPI0411688A (en) 2006-12-26
RU2348628C2 (en) 2009-03-10
IS8178A (en) 2005-12-13
JP4607107B2 (en) 2011-01-05
KR20060113625A (en) 2006-11-02
AR044990A1 (en) 2005-10-12
US20070203187A1 (en) 2007-08-30
EP1646629A2 (en) 2006-04-19
EP1646629B1 (en) 2010-06-23
AU2004256083A1 (en) 2005-01-20
JP2007521281A (en) 2007-08-02
AU2004256083B2 (en) 2007-10-11
IL172785A0 (en) 2006-06-11
NO20060558L (en) 2006-02-02
NZ544237A (en) 2008-09-26
TW200510421A (en) 2005-03-16
CL2004001678A1 (en) 2005-05-20
WO2005005398A2 (en) 2005-01-20
RU2005140379A (en) 2007-08-10
MY140137A (en) 2009-11-30
US20050038092A1 (en) 2005-02-17
CA2530140C (en) 2010-11-09
ATE471937T1 (en) 2010-07-15
MA27938A1 (en) 2006-06-01
WO2005005398A3 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
CA2530140A1 (en) Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
HRP20161171T1 (en) Amidine substituted beta-lactam compounds, their preparation and use as antibacterial agents
JP2019077725A5 (en)
ES2402882T3 (en) Bridged monobactams usable as beta-lactamase inhibitors
RU2013143028A (en) Thiazolylphenylbenzenesulfonamide derivatives as kinase inhibitors
JP2002535323A5 (en)
JP2005524660A5 (en)
CA2522024A1 (en) Cgrp receptor antagonists
JP2006506455A5 (en)
JP2018503661A5 (en)
AU2004256085B2 (en) Cyclopropyl Group Substituted Oxazolydinone Antibiotics and Derivatives Thereof
JP2005503435A5 (en)
EP1448536A1 (en) Cyclopropyl-containing oxazolidinone antibiotics and derivatives thereof
CA2449578A1 (en) Pyrrolidine oxadiazole- and thiadiazole derivatives
AU2004256084B2 (en) Oxazolidinone antibiotics and derivatives thereof
AU2001247540B2 (en) Novel benzosultam oxazolidinone antibacterial agents
JPWO2020047323A5 (en)
US20070293493A1 (en) Oxazolidinone antibiotics and derivatives thereof
JP2005537301A5 (en)
AU2002362028B2 (en) Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof
ZA200304945B (en) Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them.
RU2005115567A (en) 1-Acylpyrrolidine Derivatives for the Treatment of Viral Infections

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed